Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some fear misuse of oral agents.

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

Ellison says the settlement requires Novo Nordisk to provide insulin products—including Novolog, Tresiba, Fiasp, and Novolin, at any formulation and via any delivery method—at $35 per monthly ...

On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over ...

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater access to its human insulin and lower prices, while also protesting ...

We understand that supply disruptions of Fiasp® vials may have a significant impact on patients and Novo Nordisk takes our responsibility to resolve this situation very seriously.

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health insurers.